[225Ac]-AZD2284 / AstraZeneca - LARVOL DELTA

A Phase 1, first-in-human, dose-escalation study of [ 225 Ac]-AZD2284 (AZD2284), a STEAP2-directed radiopharmaceutical, in patients with metastatic castration-resistant prostate cancer (mCRPC) (EANM 2025) - P1 | "Enrolment began in March 2025 and is ongoing. Results None Conclusion None"

Clinical • First-in-human • Metastases • P1 data • Tumor mutational burden • Alopecia • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Immunology • Microsatellite Instability • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor • BRCA • MSI • STEAP1 • STEAP2 • TMB

AZD2284: A novel, alpha-particle emitting radioconjugate targeting STEAP2 in metastatic castration-resistant prostate cancer (AACR 2025) - "In preclinical models, AZD2284 effectively binds to and internalizes in prostate cancer cells, thereby delivering the radioisotope, [225Ac]. Biodistribution studies confirm sustained tumor uptake of AZD2284 with low normal organ uptake. Single-dose administration of AZD2284 leads to durable anti-tumor efficacy in xenograft models."

Metastases • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • STEAP2

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=134 | Recruiting | Sponsor: AstraZeneca | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=134 | Not yet recruiting | Sponsor: AstraZeneca

New P1 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor